Adjunctive Intranasal Oxytocin Reduces Symptoms in Schizophrenia Patients
Adjunctive Intranasal Oxytocin Reduces Symptoms in Schizophrenia Patients
复制标题
DOI：
10.1016/j.biopsych.2010.04.039
复制
发表时间：
2010-10-01
影响因子：
10.6
通讯作者：
Hadley, Allison
中科院分区：
文献类型：
--
作者：
Feifel, David;Macdonald, Kai;Hadley, Allison
背景：人类和动物研究都表明催产素可能具有抗精神病的特性。因此，我们进行了一项临床试验，直接测试这一概念。方法：19名精神分裂症患者的残留症状，尽管在一个稳定的剂量至少有一种抗精神病药物被纳入一项随机，双盲，交叉研究。他们接受了为期3周的每日鼻内催产素（滴定至40 IU，每天两次）和安慰剂对抗精神病药物。鼻内治疗顺序随机分配，治疗之间有1周的洗脱期。结果：对完成所有研究访问的15名受试者的分析显示，与安慰剂相比，催产素在3周终点时显著降低了阳性和阴性症状量表（p < .001）和临床总体印象改善量表（p < .001）的评分。在早期时间点未观察到获益。催产素耐受性良好，并没有产生不良影响，根据患者的报告或实验室analysis.Conclusions：结果支持这一假设，催产素具有抗精神病的性质，是耐受性良好。更高的剂量和更长的治疗时间可能会产生更大的益处，应在未来的研究中进行评估。
Background: Both human and animal studies suggest oxytocin may have antipsychotic properties. Therefore, we conducted a clinical trial to directly test this notion.Methods: Nineteen schizophrenia patients with residual symptoms despite being on a stable dose of at least one antipsychotic were enrolled in a randomized, double-blind, crossover study. They received 3 weeks of daily intranasal oxytocin (titrated to 40 IU twice a day) and placebo adjunctive to their antipsychotics. Order of intranasal treatment was randomly assigned and there was a 1-week washout between treatments.Results: Analysis of the 15 subjects who completed all the study visits revealed that oxytocin significantly reduced scores on the Positive and Negative Symptom Scale (p < .001) and Clinical Global Impression-Improvement Scale (p < .001) compared with placebo at the 3-week end point. No benefit was seen at the early time points. Oxytocin was well tolerated and produced no adverse effects based upon patient reports or laboratory analysis.Conclusions: The results support the hypothesis that oxytocin has antipsychotic properties and is well tolerated. Higher doses and longer duration of treatment may produce larger benefits and should be evaluated in future studies.